| abstract |
Herein, a prodrug hydroxylase inhibitor capable of stabilizing hypoxia-inducible factor-2 (HIF-2) as well as hypoxia-inducible factor-1 alpha (HIF-lα) is disclosed. Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Also disclosed are methods of stimulating cellular immune responses in mammals, such as increasing phagocytic action, for example, phagocytic cells, particularly keratinocytes, prolonging the life span of neutrophils. The disclosed compounds provide a method of treating a disease associated with an immune response in the body. |